Professor Russell Petty is a graduate of University of Dundee School of Medicine and he completed his initial general medical training in Dundee, Newcastle, and Hobart , then specialist and academic training in Medical Oncology in Aberdeen and Auckland. In 2007 he was appointed as a Clinical Senior Lecturer in Medical Oncology at the University of Aberdeen and promoted to Professor of Medical Oncology in 2014 . In September 2015 he was appointed as Professor of Medical Oncology at the University of Dundee and honorary consultant in Medical Oncology in Ninewells Hospital, NHS Tayside. His main research interests are in clinical and translational research in gastro-oesophageal cancers. He was the chief investigator of the recently completed COG trial which was the first Phase III randomised controlled trial of second line therapy in oesophageal cancer and lead the translational arm TRANSCOG which identified a predictive biomarker for a gefitinib responsive subgroup of tumours. He is a current member of the trial management groups for several UK national clinical trials in gastroesophageal cancer including PLATFORM and GO-2 and the translational research lead for TRANS-GO2 and TRANSCOG2. Professor Petty is the current speciality adviser in Medical Oncology to the Chief Medical officer in Scotland. He acts as a clinical expert for SMC and NICE and recently contributed to the Scottish Parliament Health and Sport Committee enquiry in to access to new medicines in Scotland and the reform of SMC process for evaluation of new medicines which included the development of the patient and clinician engagement (PACE) process . He is a current member of the NCRN UGI cancers clinical study group and the EORTC gastric cancer task force and a member of the Editorial Board of BMC Cancer.

Asa Dahle-Smith, David Stevenson, Doreen Massie, Graeme Murray, Susan Dutton, CorranRoberts, David Ferry, Aileen Osborne, Caroline Clark, Russell D Petty*, Zosia Miedzybrodzka Characterisation of Epidermal Growth Factor (EGFR) copy number aberrations in Oesophageal Carcinoma. Molecular cytogenetics 2015. In Press * Denotes equal author contribution Kasia Matula, Elaina Collie-Duguid, Graeme Murray, Khyati Parikh, Heike Grabsch, Patrick Tan, Salina Lalwani, Roberta Grau, Yuhan Ong, Gillian Bain, Asa-Dahle-Smith, Gordon Urquhart, Jacek Bielawski, Michael Finnegan and Russell D Petty. Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer. BMC Cancer 2015. In press Dahle-Smith A, Petty RD.Biomarkers and novel agents in esophago-gastric cancer: are we making progress? Expert Rev Anticancer Ther. 2015;15(9):1103-19. Susan J Dutton, David R Ferry, Jane M Blazeby, Haider Abbas MRCP, Asa Dahle-Smith, Wasat Mansoor, Joyce Thompson, Mark Harrison, Anirban Chatterjee, Stephen Falk, Angel Garcia-Alonso, David W Fyfe, Richard A Hubner, Tina Gamble, Lynnda Peachey, Mina Davoudianfar, Sarah R Pearson, Patrick Julier, Prof Janusz Jankowski, Rachel Kerr MD PhD, Russell D Petty. Gefitinib for oesophageal cancer progressing after chemotherapy: a phase III, multicentre, double-blind, placebo-controlled randomised clinical trial (COG).The Lancet Oncology 2014 , 15(8), 894 – 904. G. H. Bain, E. Collie-Duguid, G. I. Murray, F. J. Gilbert, A. Denison, F. Mckiddie, T. Ahearn, I.Fleming J. Leeds , P. Phull, K. Park, S. Nanthakumaran, H.I. Grabsch, P.Tan , A. Welch, L. Schweiger, A. Dahle-Smith, G. Urquhart, M. Finegan, and R. D. Petty. Tumour expression of Leptin is associated with chemotherapy resistance and therapy independent prognosis in gastro-oesophageal adenocarcinomas British Journal of Cancer 2014, 18, 110(6):1525-34 Petty RD, Brand G, Nanthkumaran S. Gastric Cancer in Treatment of Cancer (6th Edition), May 2014. K.Sikora and P.Price (Eds).CRC Press(London). Gordon Urquhart, Keith M Kerr, Marianne Nicolson, Peh Sun Loo , Ravi Sharma Raj Shrimali and Russell D Petty Serpin B3 is a novel biomarker for chemotherapy resistance in advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology 2013, 8(12), 1502-1509. Okines AF, Langley RE, Thompson LC, Stenning SP, Stevenson L, Falk S, Seymour M, Coxon F, Middleton GW, Smith D, Evans L, Slater S, Waters J, Ford D, Hall M, Iveson TJ, Petty RD, Plummer C, Allum WH, Blazeby JM, Griffin M, Cunningham D. Safety results from a randomized trial of peri-operative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or type II/III oesophagogastric junction (OGJ)adenocarcinoma. Ann Oncol. 2013 ;24(3):702-9 Petty RD. Exclusive rights in Gastric Cancer Genomics : Gut. 2012 ;61(5):638-40 Su Z, ………. Petty R, ………….. Jankowski JA Common variants at the MHC locus and at chromosome16q24.1 predispose to Barrett's esophagus. Esophageal Adenocarcinoma GeneticsConsortium; Welcome Trust Case Control Consortium 2. Nat Genet. 2012;44(10):1131-6. Hislop J, Mowatt G, Sharma P, Fraser C, Elders A, Jenkinson D, Vale L, Petty R. Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose. J Gastrointest Cancer. 2012, 43(2), 168-176. Hislop, J. M., Quayyum, Z., Elders, A. S., Fraser, C. M., Jenkinson, D. J., Mowatt, G., Sharma, P., Vale, L. D. & Petty, R. D. Systematic review of the clinical and cost-effectiveness of imatinib at escalated doses of 600 mg/day or 800 mg/day for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours which have progressed on treatment at a dose of 400 mg/day Asa Dahl-Smith and Russell D Petty. Developing Predictive Biomarkers in Oncology: How can we Achieve Consistent Success? Treatment Strategies-Oncology. Cambridge Research Centre, December 2010, p48-53. http://viewer.zmags.com/publication/8da7a9fc Alymani, Nayef A.; Smith, Murray D.; Williams, David J.; Petty Russell D Predictive Biomarkers for personalised anti-cancer drug use: Discovery to clinical implementation. European Journal of Cancer 2010, 46(5) , 869-879 Bain GH, Petty RD. Predicting response to treatment in gastro-oesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers. 2010;15(3):270-84. Alyamani, N; Smith, M; Williams, D, Petty R. The impact of physician attitudes on personalized prescription of novel targeted anti-cancer drugs using predictive biomarkers British Journal of Clinical Pharmacology 2010, 70(2) : 295 Gourley C , Michie CO Roxburgh P, Yap TA ,Harden S Paul J, Ragupathy K , Todd R, Petty R ,Reed N , Hayward RL , Mitchell P , Rye T, Schellens JHM , Lubinski J , Carmichael J , Kaye SB, Mackean )M, Ferguson M Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2- Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype. Journal of Clinical Oncology 2010, 28 (15) , 2505-2511. Russell D Petty, Leslie M Samuel, Graeme I Murray, Graham Macdonald,Terry O'Kelly, Malcom Loudon, Norman Binnie, Emad Aly, Aileen Mckinley,Weiguang Wang, Fiona Gilbert, Scott Semple and Elaina Collie-duguid. APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. BMC Cancer 2009 11;9:434 Collie-Duguid,E. S. R.; Petty,R. D.; Kerr,K. M. Cancer Therapy Prognosis and Target , Patent / Published Patent Application 2007 ,BOA: 0519405.5 Russell D Petty, Keith M. Kerr, Graeme I. Murray, Marianne C. Nicolson, Patrick. H. Rooney, Donald Bissett, Elaina Collie-Duguid. Tumour transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in Non-Small Cell Lung Cancer. Journal of Clinical Oncology 2006, 24, 11, 1729-1744. Russell D Petty. Is there a right (and a wrong) way to kill cancer cells? Recent Advances and Research Updates 2005, 6, 193-204, (also published with permission in Austral-Asian Journal of Cancer 2006, 5, 1, 14-21). Russell D Petty, Keith M. Kerr, Marianne C. Nicolson, Elaina Collie-Duguid Graeme I. Murray. Gene Expressing Profiling in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application. Clinical Cancer Research 2004, 10, 3237-3248. Russell D Petty and Marianne C Nicolson. Advanced Pancreatic Cancer: The case for Chemotherapy. In Key Advances in the Effective Management of Upper Gastrointestinal Malignancy. Andrew Miles (Editor); Aescuplus Medical Press Ltd., (London) September 2004. Russell D. Petty and Jim Cassidy. Novel Fluoropyrimidines: Improving the efficacy and tolerability of cytotoxic therapy. Current Cancer Drug Targets 2004, 4(2), 191-204. Russell D. Petty, Marianne C. Nicolson, Sunil Skaria, Tom Sinclair, Mathew. KoruthLeslie M. Samuel. A Phase II study of Mitomycin C, Cisplatin and protracted infusional 5-Flurorouracil (MCF) in Advanced Pancreatic Carcinoma: Efficacy and Low Toxicity. Annals of Oncology 2003, 14, 1100-1105.